Core Viewpoint - Shuoshi Bio (688399) has successfully resolved a long-standing accounts receivable issue with Urumqi Rongxin Kangda Trading Co., Ltd, resulting in a positive impact on the company's financial status for 2026 [1] Group 1: Accounts Receivable Situation - The company reported an accounts receivable balance of 6.9205 million yuan from a business collaboration with Urumqi Rongxin Kangda Trading Co., Ltd as of December 31, 2025 [1] - The accounts receivable has aged over five years, and the company has made multiple attempts to collect the debt through communication, legal letters, and lawsuits, but the debtor failed to fulfill repayment obligations [1] - The company has fully provisioned for the bad debt in accordance with accounting standards, which has been reflected in the financial statements for the relevant periods [1] Group 2: Debt Settlement Agreement - The company has actively pursued debt collection and reached a settlement agreement with the debtor, stipulating that the debtor will pay 6.0994 million yuan by January 20, 2026, as full settlement of the 6.9205 million yuan accounts receivable [1] - As of the announcement date, the debtor has fully paid the agreed amount of 6.0994 million yuan, and the debt relationship has been completely settled [1] - The recovery of this accounts receivable and the reversal of the previously provisioned bad debt is expected to have a positive impact on the company's financial condition and operating results for the year 2026 [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、应收账款基本情况 江苏硕世生物科技股份有限公司（以下简称"公司"）于 2020 年度与乌鲁 木齐融信康达商贸有限公司（以下简称"欠款方"）开展试剂销售等业务合作。 截至 2025 年 12 月 31 日，双方往来形成应收账款余额合计人民币 692.05 万元。 该笔应收账款账龄已超 5 年，公司期间已通过多次专人沟通、法律函件、提起诉 讼等方式进行催缴，欠款方未能按期履行还款义务。 根据《企业会计准则》及公司会计政策相关规定，公司已对该笔应收账款全 额计提坏账准备，相关会计处理已计入对应会计期间的财务报表。 二、回款情况 为有效化解上述应收账款回收风险，保障公司及全体股东利益，公司积极推 进催收工作，经与欠款方多次协商，于近期达成债务清偿一致意见并签署协议。 协议约定，欠款方应于 2026 年 1 月 20 日前向公司支付人民币 609.94 万元，视 为该笔 692.05 万元应收账款的全部清偿款项，若欠款方未按上述期限足额支付 款项，公司有权按照原债权金额主张权益，并 ...

Group 1 - The stock price of Shuoshi Bio (688399) closed at 79.98 yuan on January 9, 2026, representing a 16.76% increase from the previous week's price of 68.5 yuan [1] - The company reached a nearly one-year high with an intraday peak of 82.0 yuan on January 9, 2026, and a low of 67.29 yuan on January 6, 2026 [1] - Shuoshi Bio's current total market capitalization is 6.708 billion yuan, ranking 58th out of 127 in the medical device sector and 2801st out of 5182 in the A-share market [1] Group 2 - Shuoshi Bio received a government subsidy of 1.63 million yuan, which is related to income and will impact the company's profit and loss for the fiscal year 2025 [1][3] - The company held its first temporary shareholders' meeting of 2026 on January 5, 2026, where shareholders approved an amendment to increase the company's business scope [2] - A total of 76 shareholders attended the meeting, representing 41.8196% of the total voting rights, with 99.9270% voting in favor of the resolution [2][3]

Group 1 - The core point of the article is that Shuoshi Biotechnology has responded to investor inquiries, indicating that as of December 31, 2025, the total number of shareholders will be 7,302 [1]

Core Insights - The medical device sector experienced a rise of 1.14% on January 8, with Kangtong Medical leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] Medical Device Sector Performance - Kangtong Medical (301515) closed at 25.48, up 20.02% with a trading volume of 123,300 shares and a transaction value of 291 million [1] - Yuanpeng Medical (300753) closed at 42.62, up 19.99% with a trading volume of 471,600 shares and a transaction value of 1.884 billion [1] - Kefu Medical (301087) closed at 54.00, up 13.52% with a trading volume of 174,300 shares and a transaction value of 92.86 million [1] - Shuoshi Biology (688399) closed at 77.21, up 13.31% with a trading volume of 73,500 shares and a transaction value of 550 million [1] - Anbiping (688393) closed at 27.60, up 6.73% with a trading volume of 69,500 shares and a transaction value of 189 million [1] Capital Flow Analysis - The medical device sector saw a net inflow of 533 million from institutional investors, while retail investors experienced a net outflow of 450 million [2][3] - Yuanpeng Medical had a net inflow of 225 million from institutional investors, but a net outflow of 103 million from retail investors [3] - Lepu Medical (300003) had a net inflow of 181 million from institutional investors, with a net outflow of 67.8 million from retail investors [3]

Group 1 - The Shanghai Composite Index closed at 4089.45 points, above the five-day moving average, with a slight increase of 0.09% [1] - The total trading volume of A-shares reached 1,781.548 billion yuan [1] - A total of 658 A-shares have prices that surpassed the five-day moving average, with notable stocks including Zhongcheng Technology, Gangtong Medical, and Shuoshi Biology, showing divergence rates of 15.86%, 14.00%, and 8.74% respectively [1] Group 2 - Stocks with significant divergence rates include: - Zhongcheng Technology (22.67% increase, 15.86% divergence) - Gangtong Medical (20.02% increase, 14.00% divergence) - Shuoshi Biology (11.51% increase, 8.74% divergence) [1] - Other stocks with smaller divergence rates that just crossed the five-day moving average include: - Jialiqi, *ST Zhisheng, and Senyuan Shares [1]

Group 1 - The core viewpoint of the news highlights a strong performance in the medical device sector, particularly with the medical device ETF (159883) showing significant gains and attracting substantial capital inflow [1][4] - The medical device index (H30217) rose by 1.81%, with notable individual stock performances such as Kewei Medical (301087) increasing over 17% and Shuoshi Bio (688399) rising over 12% [1][3] - The medical device ETF has seen a net inflow of 9.32 billion yuan over the past three days, with a peak single-day inflow of 517 million yuan, indicating strong investor interest [1][4] Group 2 - Kewei Medical has made strategic investments in the brain-computer interface sector, including a 5.83% stake in Nulingke Medical, which focuses on implantable brain-computer interface technology [3][4] - The domestic brain-computer interface sector is experiencing significant growth, with a recent unicorn company completing approximately 2 billion yuan in financing, marking it as the second-largest financing in the field globally [4] - The medical device ETF (159883) is the largest in the market, with over 23% exposure to brain-computer interface stocks, and is expected to benefit from domestic innovation and technological advancements [4][5]

Group 1 - The stock price of Shuoshi Biotechnology (688399) closed at 68.88 yuan on January 5, 2026, with an increase of 0.55% and a turnover rate of 1.68% [1] - On January 5, 2026, the net outflow of main funds was 12.89 million yuan, while retail investors saw a net inflow of 8.82 million yuan [3] - Shuoshi Biotechnology received a government subsidy of 1.63 million yuan, which is expected to impact the company's profit and loss for the year 2025 [1][3] Group 2 - The first extraordinary general meeting of shareholders for Shuoshi Biotechnology in 2026 was held on January 5, 2026, with 76 shareholders present, representing 35,074,902 voting shares, accounting for 41.82% of the total voting rights [2] - The meeting approved a special resolution to expand the company's business scope and amend the Articles of Association, with 99.93% of the votes in favor [2] - Shanghai Tongli Law Firm confirmed the legality and validity of the meeting's procedures and voting results [2]

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Core Viewpoint - The company Shuoshi Biotechnology (688399) has received a government subsidy of 1.63 million RMB, which will impact its financial results for the fiscal year 2025 [1]. Group 1: Stock Performance - As of January 5, 2026, the stock closed at 68.88 RMB, up 0.55% from the previous trading day [1]. - The stock opened at 68.51 RMB, reached a high of 69.14 RMB, and a low of 67.97 RMB, with a trading volume of 96.52 million RMB and a turnover rate of 1.68% [1]. Group 2: Government Subsidy - The company announced it received a government subsidy of 1.63 million RMB, categorized as a revenue-related government grant [1]. - The accounting treatment and impact of this subsidy on the company's financials will be confirmed by the annual audit results [1]. - The board of directors has assured the accuracy and completeness of the announcement regarding the subsidy [1].